1. Scrip
  2. >>New Products

Gilead/Kite Gain Second CAR-T Approval With Tecartus, Price On Par With Their First

Similar CAR-T Will Carry The Same Cost As Yescarta

 
• By Mary Jo Laffler

As the first company with two approved chimeric antigen receptor T-cell therapies, Gilead’s Kite subsidiary has set a precedent by keeping the pricing the same as its first approved CAR-T, Yescarta. 

3D illustration of T cells attacking a cancer cell (CAR-T cell therapy) - Illustration

Gilead Sciences, Inc.'s Kite Pharma, Inc. subsidiary has managed to become the first company with two chimeric antigen receptor T-cell (CAR-T) therapies on the market, but its new Tecartus (brexucabtagene autoleucel, KTE-X19) is almost identical to its first CAR-T therapy, Yescarta (axibabtagene ciloleucel), and Kite is keeping the price tags the same.

Both CAR-Ts have a list price of $373,000. (Also see "Gilead/Kite Pricing For Yescarta Undercuts Novartis's CAR-T Kymriah" - Scrip, 19 October, 2017.) It had been expected that Gilead/Kite might push the price higher given potential changes coming in Medicare reimbursement for CAR-Ts, based on the new indication for mantle cell lymphoma, a rare form of non-Hodgkin lymphoma

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Verastem Wins Approval For Novel Drug Combo In Rare Ovarian Cancer

 
• By Jessica Merrill

The novel RAF/MEK inhibitor and FAK inhibitor are the first treatment approved specifically for KRAS-mutated recurrent low-grade serious ovarian cancer (LGSOC).

Pipeline Watch: Thirteen Approvals And Ten Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

J&J’s Imaavy Approval Is The Starting Line For Pipeline-In-A-Product Strategy

 
• By Jessica Merrill

The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.

More from Scrip